Compare ZS & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZS | GEHC |
|---|---|---|
| Founded | 2007 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 38.9B |
| IPO Year | 2018 | N/A |
| Metric | ZS | GEHC |
|---|---|---|
| Price | $186.30 | $83.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 12 |
| Target Price | ★ $318.42 | $88.75 |
| AVG Volume (30 Days) | 1.9M | ★ 3.5M |
| Earning Date | 03-04-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.18% |
| EPS Growth | N/A | ★ 32.35 |
| EPS | N/A | ★ 4.83 |
| Revenue | $2,833,272,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $27.01 | $6.42 |
| Revenue Next Year | $19.32 | $4.34 |
| P/E Ratio | ★ N/A | $16.31 |
| Revenue Growth | ★ 23.24 | 3.51 |
| 52 Week Low | $164.78 | $57.65 |
| 52 Week High | $336.99 | $94.80 |
| Indicator | ZS | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 25.09 | 53.47 |
| Support Level | $197.47 | $78.23 |
| Resistance Level | $229.00 | $83.21 |
| Average True Range (ATR) | 7.50 | 2.10 |
| MACD | -1.22 | -0.14 |
| Stochastic Oscillator | 15.99 | 63.79 |
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).